An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.
Tomohiro TsuchiyaKeiichiro ImanakaYuki IwakiRyo OyamaKatsuyoshi HashineAkito YamaguchiHiroji UemuraPublished in: International journal of clinical oncology (2019)
ClinicalTrials.gov identifier: NCT02162836.